Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
52
ITHUF Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
-1.1%
Day range:
$0.0049 - $0.0090
52-week range:
$0.0030 - $0.0133
Dividend yield:
0%
P/E ratio:
26.67x
P/S ratio:
0.36x
P/B ratio:
--
Volume:
1.6M
Avg. volume:
187.2K
1-year change:
66.67%
Market cap:
$54.5M
Revenue:
$167.6M
EPS (TTM):
$0.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ITHUF
iAnthus Capital Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $10.33 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | 63.1% | -- | $6.00 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -15.25% | $5.49 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.13 | -- | -43.57% | $55.19 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ITHUF
iAnthus Capital Holdings, Inc.
|
$0.0080 | -- | $54.5M | 26.67x | $0.00 | 0% | 0.36x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.62 | $16.67 | $2.1B | 27.84x | $0.00 | 0% | 8.29x |
|
EDSA
Edesa Biotech, Inc.
|
$1.76 | $10.33 | $12.4M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$1.06 | $6.00 | $23.6M | -- | $0.00 | 0% | 27.04x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.99 | $5.49 | $105.3M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$45.01 | $55.19 | $3.5B | -- | $0.00 | 0% | 473.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ITHUF
iAnthus Capital Holdings, Inc.
|
168.21% | 4.137 | 360.12% | 0.34x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 18.80x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -1.067 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | 0.195 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ITHUF
iAnthus Capital Holdings, Inc.
|
$10.9M | -$4.2M | 1.23% | -- | -12% | -$13.5M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.8K | -$1.9M | -80.33% | -80.46% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
iAnthus Capital Holdings, Inc. vs. Competitors
-
Which has Higher Returns ITHUF or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -35.45% compared to iAnthus Capital Holdings, Inc.'s net margin of 42.95%. iAnthus Capital Holdings, Inc.'s return on equity of -- beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital ITHUFiAnthus Capital Holdings, Inc.30.93% -$0.00 $131.4M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About ITHUF or AUPH?
iAnthus Capital Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 112400%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 6.7%. Given that iAnthus Capital Holdings, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe iAnthus Capital Holdings, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ITHUFiAnthus Capital Holdings, Inc.0 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is ITHUF or AUPH More Risky?
iAnthus Capital Holdings, Inc. has a beta of -0.140, which suggesting that the stock is 114.009% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock ITHUF or AUPH?
iAnthus Capital Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iAnthus Capital Holdings, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITHUF or AUPH?
iAnthus Capital Holdings, Inc. quarterly revenues are $35.4M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. iAnthus Capital Holdings, Inc.'s net income of -$12.5M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, iAnthus Capital Holdings, Inc.'s price-to-earnings ratio is 26.67x while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iAnthus Capital Holdings, Inc. is 0.36x versus 8.29x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITHUFiAnthus Capital Holdings, Inc.0.36x 26.67x $35.4M -$12.5M AUPHAurinia Pharmaceuticals, Inc.8.29x 27.84x $73.5M $31.6M
-
Which has Higher Returns ITHUF or EDSA?
Edesa Biotech, Inc. has a net margin of -35.45% compared to iAnthus Capital Holdings, Inc.'s net margin of --. iAnthus Capital Holdings, Inc.'s return on equity of -- beat Edesa Biotech, Inc.'s return on equity of -80.46%.
Company Gross Margin Earnings Per Share Invested Capital ITHUFiAnthus Capital Holdings, Inc.30.93% -$0.00 $131.4M EDSAEdesa Biotech, Inc.-- -$0.25 $14.1M -
What do Analysts Say About ITHUF or EDSA?
iAnthus Capital Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 112400%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 525%. Given that iAnthus Capital Holdings, Inc. has higher upside potential than Edesa Biotech, Inc., analysts believe iAnthus Capital Holdings, Inc. is more attractive than Edesa Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ITHUFiAnthus Capital Holdings, Inc.0 0 0 EDSAEdesa Biotech, Inc.1 0 0 -
Is ITHUF or EDSA More Risky?
iAnthus Capital Holdings, Inc. has a beta of -0.140, which suggesting that the stock is 114.009% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock ITHUF or EDSA?
iAnthus Capital Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iAnthus Capital Holdings, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITHUF or EDSA?
iAnthus Capital Holdings, Inc. quarterly revenues are $35.4M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. iAnthus Capital Holdings, Inc.'s net income of -$12.5M is lower than Edesa Biotech, Inc.'s net income of -$1.7M. Notably, iAnthus Capital Holdings, Inc.'s price-to-earnings ratio is 26.67x while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iAnthus Capital Holdings, Inc. is 0.36x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITHUFiAnthus Capital Holdings, Inc.0.36x 26.67x $35.4M -$12.5M EDSAEdesa Biotech, Inc.31.22x -- -- -$1.7M
-
Which has Higher Returns ITHUF or LEXX?
Lexaria Bioscience Corp. has a net margin of -35.45% compared to iAnthus Capital Holdings, Inc.'s net margin of -2178.51%. iAnthus Capital Holdings, Inc.'s return on equity of -- beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital ITHUFiAnthus Capital Holdings, Inc.30.93% -$0.00 $131.4M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About ITHUF or LEXX?
iAnthus Capital Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 112400%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 403.14%. Given that iAnthus Capital Holdings, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe iAnthus Capital Holdings, Inc. is more attractive than Lexaria Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings ITHUFiAnthus Capital Holdings, Inc.0 0 0 LEXXLexaria Bioscience Corp.0 0 0 -
Is ITHUF or LEXX More Risky?
iAnthus Capital Holdings, Inc. has a beta of -0.140, which suggesting that the stock is 114.009% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.
-
Which is a Better Dividend Stock ITHUF or LEXX?
iAnthus Capital Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iAnthus Capital Holdings, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITHUF or LEXX?
iAnthus Capital Holdings, Inc. quarterly revenues are $35.4M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. iAnthus Capital Holdings, Inc.'s net income of -$12.5M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, iAnthus Capital Holdings, Inc.'s price-to-earnings ratio is 26.67x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iAnthus Capital Holdings, Inc. is 0.36x versus 27.04x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITHUFiAnthus Capital Holdings, Inc.0.36x 26.67x $35.4M -$12.5M LEXXLexaria Bioscience Corp.27.04x -- $174K -$2.7M
-
Which has Higher Returns ITHUF or ONCY?
Oncolytics Biotech, Inc. has a net margin of -35.45% compared to iAnthus Capital Holdings, Inc.'s net margin of --. iAnthus Capital Holdings, Inc.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital ITHUFiAnthus Capital Holdings, Inc.30.93% -$0.00 $131.4M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About ITHUF or ONCY?
iAnthus Capital Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 112400%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 452.93%. Given that iAnthus Capital Holdings, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe iAnthus Capital Holdings, Inc. is more attractive than Oncolytics Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ITHUFiAnthus Capital Holdings, Inc.0 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is ITHUF or ONCY More Risky?
iAnthus Capital Holdings, Inc. has a beta of -0.140, which suggesting that the stock is 114.009% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock ITHUF or ONCY?
iAnthus Capital Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iAnthus Capital Holdings, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITHUF or ONCY?
iAnthus Capital Holdings, Inc. quarterly revenues are $35.4M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. iAnthus Capital Holdings, Inc.'s net income of -$12.5M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, iAnthus Capital Holdings, Inc.'s price-to-earnings ratio is 26.67x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iAnthus Capital Holdings, Inc. is 0.36x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITHUFiAnthus Capital Holdings, Inc.0.36x 26.67x $35.4M -$12.5M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns ITHUF or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -35.45% compared to iAnthus Capital Holdings, Inc.'s net margin of -867.29%. iAnthus Capital Holdings, Inc.'s return on equity of -- beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital ITHUFiAnthus Capital Holdings, Inc.30.93% -$0.00 $131.4M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About ITHUF or XENE?
iAnthus Capital Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 112400%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.19 which suggests that it could grow by 22.62%. Given that iAnthus Capital Holdings, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe iAnthus Capital Holdings, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ITHUFiAnthus Capital Holdings, Inc.0 0 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is ITHUF or XENE More Risky?
iAnthus Capital Holdings, Inc. has a beta of -0.140, which suggesting that the stock is 114.009% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.
-
Which is a Better Dividend Stock ITHUF or XENE?
iAnthus Capital Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iAnthus Capital Holdings, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITHUF or XENE?
iAnthus Capital Holdings, Inc. quarterly revenues are $35.4M, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. iAnthus Capital Holdings, Inc.'s net income of -$12.5M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, iAnthus Capital Holdings, Inc.'s price-to-earnings ratio is 26.67x while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iAnthus Capital Holdings, Inc. is 0.36x versus 473.02x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITHUFiAnthus Capital Holdings, Inc.0.36x 26.67x $35.4M -$12.5M XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 31.68% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 45.78% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.15% over the past day.
